1. Which of the following best describes the updated definition of pulmonary hypertension (PH) in terms of mean pulmonary arterial pressure (mPAP)?

2. Susan is a 47-year-old woman with a 6-month history of idiopathic pulmonary arterial hypertension (IPAH). Her symptoms were initially characterized as World Health Organization (WHO) functional class (FC) II with a low risk of 1-year mortality (< 5%). Her mPAP was 26 mmHg with PVR of 3.2 Wood units with normal right ventricular function by echocardiography. She was vasoreactive and does not have any comorbidities. Which of the following would be the most appropriate treatment to start Susan on?

3. The REVEAL risk calculator was derived, validated and recently updated to REVEAL 2.0. Which of the following best describe the new variables in the updated REVEAL 2.0 risk calculator?

4. Amber is a 60-year-old and was referred to a pulmonologist after having progressive dyspnea with occasional chest pain over the past few months. She is slightly overweight and has a history of asthma. She used to be physically active but now has difficulty performing daily tasks. Echocardiographic signs of pulmonary hypertension were present, such as peak tricuspid regurgitation velocity of 3.6 m/s and a pulmonary artery diameter of 27 mm. Additional work up determined she was at intermediate risk for PAH. She was referred to an expert PAH center; right heart catheterization confirmed diagnosis of idiopathic PAH with an mPAP of 28 mmHg. What would be the appropriate action at this time?

5. In terms of patient benefit of appropriate PAH therapies, a meta-analysis evaluating the impact of combination therapy in PAH demonstrated which of the following?

« Return to Activity